News

A fingerprint of exhaled breath
Enlarge image

ResearchSwitzerland

A fingerprint of exhaled breath

04.04.2013 - Researchers from ETH Zurich have shown that the individual fingerprint of exhaled breath can be used for diagnostic purposes.

The team headed by Renato Zenobi reports in the journal PLoS that real-time analysis of the metabolic pattern found in exhaled breath can help to diagnose and monitor diseases. Using mass spectrometry (SESI-MS), the ETH researchers found that the chemical "fingerprint" of exhaled breath of 11 volunteers showed an individual core pattern and remained stable over time. According to the researchers, linking up that metabolic ID with genetic susceptibility to diseases can help diagnosing manifestation of diseases more individually. Shortly before, US researchers had published results of a MS-based study for diagnosis of heart failure

"We did find some small variations during the day, but overall the individual pattern stays sufficiently constant to be useful for medical purposes," says Pablo Martinez-Lozano Sinues, senior scientist in Zenobi's research group. To carry out these measurements, Zenobi and his colleagues modified commercial mass spectrometers by adding a breath sampling inlet line that delivers exhaled breath from a mouth piece directly into the ion source of the instrument. Mass spectra showing peaks of roughly 100 compounds in breath can be easily and rapidly obtained. 

The researchers are working to recognise characteristic patterns of lung diseases with the same technology. Although the potential usefulness of analysing breath for medical diagnosis has been known, it is rarely done in academic medicine. "This might be due to the fact that existing methods for breath analysis are either rather slow, or are limited to a small number of compounds that they can detect," says Sinues. Compared to analysis of blood or urine, a significant advantage of the ETH researchers’ approach is that the breath fingerprint is available within seconds. Another benefit is that exhaling into the ion source of a mass spectrometer is completely non-invasive. They researchers see huge potential to use the method as a tool for early detection of certain diseases in risk populations and in therapy monitoring.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/a-fingerprint-of-exhaled-breath.html

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

M&AIreland

08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.

BusinessIreland

07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.

BusinessSwitzerland

03.07.2015 Biotech giant Biogen is investing CHF1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, Biogen will create up to 400 jobs at the new plant.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • KAROLINSKA (S)12.95 SEK8.37%
  • IXICO (UK)35.50 GBP5.97%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • MEDIGENE (D)9.65 EUR-10.32%
  • SERODUS (N)3.08 NOK-8.88%
  • ZELTIA (E)3.69 EUR-8.44%

TOP

  • IXICO (UK)35.50 GBP57.8%
  • DBV TECHNOLOGIES (F)75.75 EUR43.9%
  • ADOCIA (F)88.67 EUR28.9%

FLOP

  • BIOTEST (D)25.26 EUR-64.3%
  • BIOTECH PHARMACON (N)9.44 NOK-47.6%
  • TRANSGENE (F)2.95 EUR-39.4%

TOP

  • ADOCIA (F)88.67 EUR532.9%
  • VERONA PHARMA (UK)4.88 GBP324.3%
  • FORMYCON (D)28.20 EUR305.8%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEOVACS (F)1.05 EUR-69.6%
  • BIOTEST (D)25.26 EUR-69.3%

No liability assumed, Date: 27.07.2015